The impact of clinical trials of drugs on the investigator, the industry and the country
Elliott, G.A.
South African Medical Journal 44(1): 5-7
1970
ISSN/ISBN: 0256-9574 PMID: 4904996 Document Number: 23719
Document emailed within 1 workday
Related Documents
Whitney, H.A.; Covington, T.R. 1971: The future impact of clinical pharmacy on parenteral drugs and the industry Bulletin of the Parenteral Drug Association 25(2): 87-97Hamada, C. 2015: Statistical Viewpoints on Designing Investigator Initiated Clinical Trials Nihon Geka Gakkai Zasshi 116(3): 176-180
Kingma, F.J. 1972: Role of the clinical investigator in clinical trials Journal of the American Veterinary Medical Association 161(11): 1389-1390
McKinley, R.E. 1972: Clinical trials from the industry viewpoint Journal of the American Veterinary Medical Association 161(11): 1391-1394
Miki, S. 2007: Why multi-national clinical trials now?--Industry perspective Gan to Kagaku Ryoho. Cancer and ChemoTherapy 34(2): 293-296
Jia, S.; Brown, D.; Wall, A.; Kodner, I.; Keune, J.D. 2013: Industry-sponsored clinical trials: the problem of conflicts of interest Bulletin of the American College of Surgeons 98(5): 32-35
Bellamy, N.; Anastassiades, T.P.; Buchanan, W.W.; Davis, P.; Lee, P.; McCain, G.A.; Wells, G.A.; Campbell, J. 1991: Rheumatoid arthritis antirheumatic drug trials. II. Tables for calculating sample size for clinical trials of antirheumatic drugs Journal of Rheumatology 18(12): 1901-1907
Pai, M.; Colford, J.M. 2002: Clinical trials in India sponsored by the pharmaceutical industry: a proposal for reforms National Medical Journal of India 15(2): 93-96
Richman, D.; Itri, L.; Johnson, M.F.; Eigo, J. 1990: Methodological issues in AIDS clinical trials. Discussion. Design of clinical trials--active control (equivalence) trials Journal of Acquired Immune Deficiency Syndromes 3 Suppl. 2: S88
Lal, A.; Sharma, M.L. 1992: An assessment of clinical trials with drugs Indian Journal of Physiology and Pharmacology 36(2): 143-145
Peng, Y.; Li, P-ping.; Li, L.; Zhang, Y.; Hou, W-zhen.; Cui, D-dan.; Li, J.; Wang, L.; Wang, Q-li.; Wang, X-liang. 2016: Progress of clinical trials in Alzheimer's disease drugs Yao Xue Xue Bao 51(8): 1185-1195
Miller, B.L. 1980: Placebo usage in clinical trials of lifesaving drugs Progress in Clinical and Biological Research 38: 263-274
Miller, B.L. 1980: Placebo usage in clinical trials of lifesaving drugs Progress in Clinical and Biological Research 38: 263-274
Takashima, A.; Fukuda, H.; Shibata, T. 2010: Development for and clinical trials of molecular targeting drugs Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(5): 822-827
Plat, F. 1992: Methodology of phase Ii clinical trials of hypocholesteremic drugs: which criteria? Archives des Maladies du Coeur et des Vaisseaux 85(Special Issue 2): 117-120
Lietman, P.; Temple, R.; Harrington, M.; Peck, C. 1990: Methodological issues in AIDS clinical trials. Discussion. Design of clinical trials--approaches to clinical trials design Journal of Acquired Immune Deficiency Syndromes 3 Suppl. 2: S27
Bartus, R.T.; Dean, R.L.; Beer, B. 1983: An evaluation of drugs for improving memory in aged monkeys: implications for clinical trials in humans Psychopharmacology Bulletin 19(2): 168-184
Ivers, N.M.; Taljaard, M.; Dixon, S.; Bennett, C.; McRae, A.; Taleban, J.; Skea, Z.; Brehaut, J.C.; Boruch, R.F.; Eccles, M.P.; Grimshaw, J.M.; Weijer, C.; Zwarenstein, M.; Donner, A. 2011: Impact of CONSORT extension for cluster randomised trials on quality of reporting and study methodology: review of random sample of 300 trials, 2000-8 Bmj 343: D5886
Dancey, J.E.; Schoenfeldt, M. 2003: Clinical trials referral resource. Current clinical trials of agents targeting epidermal growth factor receptor Oncology 17(6): 819; 826
Davis, T.; Gore-Langton, R.E.; Cheson, B.D. 2000: Clinical trials referral resource. Current clinical trials of the anti-CD20 monoclonal antibody rituximab Oncology 14(10): 1437; 1440-1443